Analytical Data
-
基因名
Siglec-3/CD33
-
简介
Siglec-3/CD33 protein is a sialic acid-binding lectin that mediates cell-cell interactions and maintains immune cell quiescence. It prefers α-2,3- and α-2,6-linked glycans with sialic acid. Siglec-3/CD33 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived Siglec-3/CD33 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
别名
CD33 molecule; CD33; FLJ00391; gp67; Siglec3; Siglec-3; p67
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-7*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P20138-1
-
表达区间
D18-H259
-
蛋白长度
Extracellular Domain
-
分子量
48-58 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-3, also known as CD33, is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family and plays a crucial role in the immune system by regulating sialic acid recognition and modulating immune cell signaling. Research into Siglec-3/CD33 has intensified due to its implications in various diseases, particularly in the context of hematological malignancies such as acute myeloid leukemia (AML) and its potential as a therapeutic target. CD33 is primarily expressed on myeloid lineage cells and is involved in inhibiting immune responses through its receptor-ligand interactions. The exploration of recombinant CD33 proteins has facilitated the understanding of its structure, function, and interactions with ligands, opening avenues for developing targeted therapies, such as monoclonal antibodies and immunotherapeutics that can selectively engage CD33-expressing cells. Additionally, its role in modulating immune cell activity makes it a candidate for combination therapies to enhance anti-tumor immunity. Ongoing studies are focused on elucidating the precise mechanisms by which Siglec-3/CD33 influences immune responses and identifying biomarkers for patient stratification in CD33-targeted therapies. This research background underscores the importance of Siglec-3/CD33 in both basic immunology and clinical applications, highlighting its potential as a pivotal player in the treatment of immune-related disorders and cancers.
